Aditum Bio and Leads Biolabs join forces to fight autoimmune …
Nov 7, 2024 · The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new company that will develop a potentially first-in-class tri-specific T cell engager for the treatment of difficult-to-treat autoimmune diseases.
BridgeBio wins FDA Approval for cardiomyopathy treatment
Nov 26, 2024 · The exact prevalence of ATTR-CM is uncertain but is thought to be higher than previously thought. Estimates have increased from 5 in 100,000 people in 2004 to 35 per 100,000 people in 2022.
FDA removes clinical hold on Novavax’s COVID-19-influenza …
Nov 12, 2024 · The U.S. company Novavax announced yesterday that the FDA has removed the clinical hold placed on its COVID-19-influenza combination (CIC) vaccine and the stand-alone influenza vaccine candidates, which was enforced on October 16, 2024.
Relation and GSK join forces to advance fibrotic diseases and ...
Dec 10, 2024 · Big pharma company GSK and UK AI-biotech Relation Therapeutics have entered into two strategic collaborations to identify and validate new therapeutic targets for osteoarthritis and fibrotic diseases.
BMS achieves FDA approval for schizophrenia drug Cobenfy
Oct 1, 2024 · Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in equity value that completed earlier this year. The deal has paid off as Karuna’s lead asset was approved last week by the US FDA.. Cobenfy is a combination of xanomeline, which acts on the muscarinic receptor system by activating it and trospium, which blocks the muscarinic ...
Nucleus RadioPharma secures Series A investment from AstraZeneca
Jun 6, 2024 · Nucleus RadioPharma, a leading player in the development, manufacturing, and supply chain management of radiopharmaceuticals, has announced a significant milestone with the closing of a Series A extension round, featuring a new investment from AstraZeneca.
Vicebio closes $100m financing round to advance multivalent …
Sep 24, 2024 · London-based biopharmaceutical company Vicebio has announced a $100 million series B financing led by TCGX and with the participation of Goldman Sachs Alternatives, Avoro Ventures, venBio, UniQuest and Medicxi.
Biopharmaceutical Manufacturing, Upstream, Downstream …
5 days ago · News on the biopharmaceutical manufacturing industry, focusing on biologics, technology, upstream/downstream processing, cell culture and regulations
Biosimilars overview: Formycon assesses the space
Nov 20, 2024 · There are probably 10% to 20% of the competitors in the biosimilars market compared to generics, where there are hundreds of players. I would say in biosimilars there are a good dozen of serious players today, partly because there was some consolidation at …
Biohaven’s myostatin inhibitor fails in phase 3 spinal muscular …
Nov 26, 2024 · Biohaven announced this week that its phase 3 trial of taldefgrobep alfa, a recombinant protein targeting myostatin, had failed to meet its primary endpoint in patients with spinal muscular atrophy.